L’ostéoporose cortisonique

1996, Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis, Arthritis Rheum, 39, 1791, 10.1002/art.1780391104 2001, Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis, Arthritis Rheum, 44, 1496, 10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5 Manolagas, 1999, New developments in the pathogenesis and treatment of steroid-induced osteoporosis, J Bone Miner Res, 14, 1061, 10.1359/jbmr.1999.14.7.1061 Orcel, 2001, Ostéoporose cortisonique, Rev rhum [Ed Fr], 68, 678, 10.1016/S1169-8330(01)00181-8 Roux, 2000, Bone loss. Factors that regulate osteoclast differentiation: an update, Arthitis Res, 2, 451, 10.1186/ar127 Weinstein, 2000, The pathogenesis of glucocorticoid-induced osteoporosis, Clin Exp Rheumatol, 18, S35 Walsh, 1996, Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study, Br Med J, 313, 344, 10.1136/bmj.313.7053.344 Van Staa, 2000, Use of oral corticosteroids in the United Kingdom, QJM, 93, 105, 10.1093/qjmed/93.2.105 Gudbjornsson, 2002, Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice, Ann Rheum Dis, 61, 32, 10.1136/ard.61.1.32 Lukert, 1990, Glucocorticoid-induced osteoporosis: pathogenesis and management, Ann Intern Med, 112, 352, 10.7326/0003-4819-112-5-352 Van Staa, 2000, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology (Oxford), 39, 1383, 10.1093/rheumatology/39.12.1383 Van Staa, 2000, Use of oral corticosteroids and risk of fractures, J Bone Miner Res, 15, 993, 10.1359/jbmr.2000.15.6.993 Levis, 1998, Bone densitometry: clinical considerations, Arthritis Rheum, 41, 577, 10.1002/1529-0131(199804)41:4<577::AID-ART4>3.0.CO;2-7 Locascio, 1990, Bone loss in response to long-term glucocorticoid therapy, Bone and Mineral, 8, 39, 10.1016/0169-6009(91)90139-Q Verhoeven, 1997, Systemic review of corticosteroid-induced osteoporosis in rheumatoid arthritis and other diseases, Br J Rheumatol, 36, 67 Dykman, 1985, Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases, Arthritis Rheum, 28, 361, 10.1002/art.1780280402 Adinoff, 1983, Steroid-induced fractures and bone loss in patients with asthma, N Engl J Med, 309, 265, 10.1056/NEJM198308043090502 Bijlsma, 1988, Bone metabolism in patients with rheumatoid arthritis, Clin Rheumatol, 7, 1623, 10.1007/BF02284051 El Maghraoui, 1999, Osteoporosis, body composition and bone turnover in ankylosing spondylitis, J Rheumatol, 26, 2205 Maillefert, 2001, Changes in bone density in patients with ankylosing spondylitis: a two year follow-up study, Osteoporosis Int, 12, 605, 10.1007/s001980170084 El Maghraoui, 2004, Osteoporosis and ankylosing spondylitis, Bone Joint Spine, 71, 291, 10.1016/j.jbspin.2003.06.002 Bijlsma, 1988, Effect of oral calcium and vitamin D on glucocorticosteroid-induced osteopenia, Clin Exp Rheumatol, 6, 113 Amin, 1999, The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach, Arthritis Rheum, 42, 1740, 10.1002/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E Buckley, 1996, Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis, Ann Intern Med, 125, 961, 10.7326/0003-4819-125-12-199612150-00004 Homik, 2000, Calcium and vitamin D for corticosteroid-induced osteoporosis Cochrane review Reginster, 1999, Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis, Osteoporos Int, 9, 75, 10.1007/s001980050118 Hall, 1994, Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids, Arthritis Rheum, 37, 1499, 10.1002/art.1780371014 Lane, 1998, Parathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: results of a randomized controlled trial, J Clin Invest, 102, 1627, 10.1172/JCI3914 2002, principal results from the Women's Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Reid, 1996, Testosterone therapy in glucocorticoid-treated men, Arch Intern Med, 156, 1173, 10.1001/archinte.1996.00440100065008 Drinkwater, 1986, Bone mineral density after resumption of menses in amenorrheic women, JAMA, 256, 380, 10.1001/jama.1986.03380030082032 Drinkwater, 1984, Bone mineral content of amenorrheic and eumenorrheic athletes, N Engl J Med, 311, 277, 10.1056/NEJM198408023110501 Delmas, 1997, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women, N Engl J Med, 337, 1641, 10.1056/NEJM199712043372301 Ettinger, 1999, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial, JAMA, 282, 637, 10.1001/jama.282.7.637 Adachi, 1997, Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis, N Engl J Med, 337, 382, 10.1056/NEJM199708073370603 Roux, 1998, Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss, J Clin Endocrinol Metab, 83, 1128, 10.1210/jc.83.4.1128 Saag, 1998, Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis, N Engl J Med, 339, 292, 10.1056/NEJM199807303390502 Adachi, 2001, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial, Arthritis Rheum, 44, 202, 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W Reid, 2000, Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial, J Bone Miner Res, 15, 1006, 10.1359/jbmr.2000.15.6.1006 Cohen, 1999, Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Arthritis Rheum, 42, 2309, 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K Boutsen, 2001, Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone, J Bone Miner Res, 16, 104, 10.1359/jbmr.2001.16.1.104 Reid, 2002, Intravenous zoledronic acid in postmenopausal women with low bone mineral density, N Engl J Med, 346, 653, 10.1056/NEJMoa011807 Adachi, 1997, Salmon calcitonin nasal spray and the prevention of corticosteroid-induced osteoporosis, Br J Rheumatol, 36, 255, 10.1093/rheumatology/36.2.255 Cranney, 2000, Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis Cochrane review Kotaniemi, 1996, Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active RA receiving low-dose glucocorticoid?, J Rheumatol, 23, 1875 Lems, 1997, Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis, Osteoporos Int, 7, 575, 10.1007/BF02652565 Lems, 1997, Is the addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid-induced osteoporosis?, Ann Rheum Dis, 56, 357, 10.1136/ard.56.6.357 Lindsay, 1997, Randomized controlled study of effect of parathyroid hormone on vertebral bone mass among postmenopausal women with osteoporosis, Lancet, 350, 550, 10.1016/S0140-6736(97)02342-8 Lane, 2000, Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial, J Bone Miner Res, 15, 944, 10.1359/jbmr.2000.15.5.944 Adami, 1991, The prevention of corticosteroid-induced osteoporosis with nandroline deconoate, Bone Miner, 15, 72, 10.1016/0169-6009(91)90111-C Greco, 1990, Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate, Calcif Tissue Int, 46, 294, 10.1007/BF02563818